Additional excipient justification [Dissolution / BCS / IVIVC]

posted by Dr_Dan  – Germany, 2014-12-02 10:34 (4212 d 14:41 ago) – Posting: # 13964
Views: 7,818

Dear all
Some time ago I started a discussion about excipients (see this link) which faded out without result. So I thought this might be a good opportunity to restart. I would like to know if there is a chance to justify a different qualitative composition for a biowaiver if well established excipients are used (Lactose, Microcrystalline Cellulose, Magnesium Stearate, Croscarmellose Sodium, Colloidal Silicon Dioxide, Hydroxypropyl Cellulose Starch, Sodium Starch etc.). My Problem is that you will find an endless number of papers describing an impact of an excipient on a special drug substance. What I need is a rationale that at least for drugs considered for a biowaiver the difference in qualitative composition would not affect the in-vivo performance as long as in vitro dissolution tests show similarity between the test product and the reference.
Do you have an idea? I am looking Forward to your reply.
Kind regards
Dr_Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
136 visitors (0 registered, 136 guests [including 24 identified bots]).
Forum time: 02:15 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5